All News

    Neoadjuvant Chemotherapy Plus Chemoradiation Safe, Effective in Bladder Cancer

    February 21st 2025, 4:00pm

    Article

    For some patients with bladder cancer, neoadjuvant chemotherapy plus bladder-saving concurrent chemoradiation therapy was effective in the long term.

    Tuspetinib Triplet Is Safe and Has Antileukemic Activity in Newly Diagnosed AML

    February 21st 2025, 2:00pm

    Article

    Treatment with tuspetinib in combination with Venclexta and Vidaza in newly diagnosed acute myeloid leukemia showed safety and antileukemic activity.

    Ficerafusp Alfa Trial Begins for Recurrent/Metastatic Head and Neck Cancer

    February 20th 2025, 10:00pm

    Article

    Ficerafusp alfa enters phase 2/3 trial for recurrent/metastatic head and neck cancer, evaluating its combination with Keytruda for first-line treatment.

    Real-World Data Confirms Safety of Bavencio and Inlyta in Advanced RCC

    February 20th 2025, 8:05pm

    Article

    In a real-world analysis of patients with advanced RCC, the combination of first-line Bavencio and Inlyta was effective and safe.

    How Pets Can Provide Hope for Patients With Bladder Cancer

    February 20th 2025, 6:00pm

    Article

    My pet provided emotional support and helped me tolerate chemotherapy better, reducing my stress and improving my well-being throughout my cancer journey.

    Personalized Cancer Vaccine Demonstrates Responses in Kidney Cancer

    February 20th 2025, 5:00pm

    Video

    Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a vaccine.

    Krazati and Erbitux Combo Benefits KRAS G12C+ Metastatic Colorectal Cancer

    February 20th 2025, 4:00pm

    Video

    Dr. Nataliya Uboha explained the benefit of treatment with Krazati combined with Erbitux in KRAS G12C–mutant metastatic colorectal cancer.

    Bavencio and BSC Extends Survival in Bladder Cancer, Regardless of Diabetes Status

    February 20th 2025, 2:00pm

    Article

    Patients with advanced urothelial carcinoma had prolonged survival with Bavencio and BSC treatment, regardless of diabetes mellitus status.

    Bavencio Maintenance After Inlyta Interruption Shows Feasibility in mRCC

    February 19th 2025, 10:00pm

    Article

    Updated TIDE-A study findings show that maintenance Bavencio with Inlyta treatment interruption is feasible in patients with metastatic renal cell carcinoma.

    Understanding the FDA Approval of Enhertu in HER2-Low and -Ultralow Breast Cancer

    February 19th 2025, 8:00pm

    Article

    Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow breast cancer.